Medarex Reports Preclinical Data on Multiple Antibody-Drug Conjugate Candidates at American Association for Cancer Research Meeting

Printer friendly version
Medarex Reports Preclinical Data on Multiple Antibody-Drug Conjugate Candidates at American Association for Cancer Research Meeting
PRINCETON, N.J., April 16 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX)
announced today that preclinical data from several investigational antibody-drug
conjugate candidates in development, each in separate studies, demonstrated enhanced
anti-tumor activity in xenograft models when compared to the anti-cancer antibodies
alone. The use of antibody- drug conjugate candidates is another new strategy to
fight cancer by targeting molecules implicated in disease (including B7-H4,
prostate-specific membrane antigen, mindin/RG1, CD70 and Ptk7) with antibodies
linked to cytotoxic agents that are designed to kill cancer cells. Results from the
preclinical studies were presented at the Annual Meeting of the American Association
for Cancer Research (AACR), being held April 12-16, 2008 in San Diego.

    "Our research and expertise in the antibody field continues to broaden our
pipeline with potentially important anti-cancer agents," said Howard H. Pien,
President and CEO of Medarex. "We are encouraged by the single-dose efficacy
observed in animal models from our antibody-drug conjugate technology platform, and
remain on track to prepare for our first antibody-drug conjugate candidate IND
filing this year."

    About Medarex

    Medarex is a biopharmaceutical company focused on the discovery, development and
potential commercialization of fully human antibody-based therapeutics to treat
life-threatening and debilitating diseases, including cancer, inflammation,
autoimmune disorders and infectious diseases. Medarex applies its UltiMAb(R)
technology and product development and clinical manufacturing experience to
generate, support and potentially commercialize a broad range of fully human
antibody product candidates for itself and its partners. More than 40 of these
therapeutic product candidates derived from Medarex technology are in human clinical
testing or have had INDs submitted for such trials, with seven of the most advanced
product candidates currently in Phase 3 clinical trials or the subject of regulatory
applications for marketing authorization. Medarex is committed to building value by
developing a diverse pipeline of antibody products to address the world's unmet
healthcare needs. For more information about Medarex, visit its website at
www.medarex.com.

    Medarex Statement on Cautionary Factors

    Except for the historical information presented herein, matters discussed herein
relating to the preclinical data on multiple antibody-drug conjugate candidates may
constitute forward-looking statements that are subject to certain risks and
uncertainties that could cause actual results to differ materially from any future
results, performance or achievements expressed or implied by such statements.
Statements that are not historical facts, including statements preceded by, followed
by, or that include the words "potential"; "may"; or similar statements are
forward-looking statements. Medarex disclaims, however, any intent or obligation to
update these forward- looking statements. Risks and uncertainties include risks
associated with product development, unforeseen safety issues resulting from the
administration of antibody products in humans, as well as risks detailed from time
to time in Medarex's public disclosure filings with the U.S. Securities and Exchange
Commission (SEC), including its Annual Report on Form 10-K for the fiscal year ended
December 31, 2007 and its quarterly reports on Form 10-Q. There can be no assurance
that future milestone payments will be paid, whether the product development efforts
will succeed, or whether other developed products will receive required regulatory
clearance or that, even if such regulatory clearance were received, such products
would ultimately achieve commercial success.  Copies of Medarex's public disclosure
filings are available from its investor relations department.

    Medarex(R), the Medarex logo and UltiMAb(R) are registered trademarks of
Medarex, Inc. All rights are reserved.

SOURCE  Medarex, Inc.
    -0-                             04/16/2008
    /CONTACT:  Laura S. Choi, Investor Relations, +1-609-430-2880, x2216, or Nichol
Harber, Corporate Communications (media), +1-609-430-2880, x2214, or Jean Mantuano,
Corporate Communications (media), +1-609-430-2880, x2221/
    /Company News On-Call:  http://www.prnewswire.com/comp/108265.html/
    /Web site:  http://www.medarex.com /
    (MEDX)

CO:  Medarex, Inc. ST:  New Jersey, California IN:  HEA MTC BIO SU:  TDS SVY

AZ-MG -- NEW033 -- 5914 04/16/2008 08:00 EDT http://www.prnewswire.com